Q-Med's six months report
Q-MED's interim report for the first half of 1999 - continued strong growth *Sales increased by 83% to SEK 66 (36) million *Income after financial items increased to SEK 12.5 (7.9) million *Launch of the urology product Deflux® for vesicoureteral reflux (VUR) *Distribution agreement for Restylane® reached for several new markets Revenues and income Q-Med's sales during the first half of 1999 amounted to SEK 65.9 million, an increase of 83% compared with the previous year. Sales for the second quarter amounted to SEK 36.3 million, an increase of 58% from the previous year and 22% from the